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Abstract
Background
End-stage renal disease (ESRD) is related to high morbidity, mortality, and impaired health-
related quality of life. While hemodialysis (HD) is the current life-saving standard of treat-
ment for patients with ESRD, their quality of life (QoL) remains far from desirable. Online
HDF (OL-HDF), due to its convenience, could improve the QoL of patients with ESRD, how-
ever, this remains uncertain.
Objective
We aimed to assess the body of evidence of OL-HDF compared to HD regarding QoL in
patients with ESRD.
Methods
We comprehensively searched in multiple data bases from their inception to February 2018.
Reviewers working independently and in duplicate appraised the quality and included ran-
domized controlled trials (RCTs) that evaluated, in patients with ESRD and HD or OL-HDF,
QoL (Short Form Health Survey with 36 questions (SF-36) with physical component score
(PCS) and mental component score (MCS) as well as scores about social activity, fatigue,
and emotion). A meta-analysis of each outcome of interest was performed using a random-
effects model.
Results
Six moderate quality RCTs met the inclusion criteria. Meta-analysis of 4 RCTs including a
total of 1,209 patients showed that OL-HDF was associated with a lower yet non-significant
score of PCS: MD (mean difference) -0.77 (95% CI -1.94 to 0.41, p = 0.20), and MCS: MD
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-1.25 (95% CI -3.10 to 0.59, p = 0.18); indicating a poorer QoL in patients on OL-HDF. Meta-
analysis of 4 RCTs including a total of 845 patients showed OL-HDF was associated with a
significant increase in the score of social activity compared to HD: SMD (standardized mean
difference): 1.95 (95% CI 0.05 to 3.86, p = 0.04), indicating a better QoL in patients on OL-
HDF; but regarding fatigue and emotion, there was no significant improvement when com-
pared to HD by meta-analysis of 3 RCTs (133 patients).
Conclusions
The body of evidence suggests that OL-HDF does not improve QoL in patients with ESRD
when compared to HD.
Introduction
For any healthcare system, the increasing number of patients with end-stage renal disease
(ESRD) is a major concern and health priority. Globally, over 2 million people receive treat-
ment with dialysis or a kidney transplant [1], and more than 700,000 patients per year in the
United States are affected by ESRD. Hemodialysis (HD) is a life-saving and the current stan-
dard of treatment for patients with ESRD. However, survival rate and quality of life (QoL) of
patients in this scenario is far from desirable.
Previous studies suggest that convective modalities such as hemofiltration (HF) and hemo-
diafiltration (HDF) are associated with better removal of both small and middle molecules as
well as greater hemodynamic stability, improved survival, and better QoL of patients with
ESRD, compared with standard HD [2–7]. HDF combines diffusive and convective clearance
of uremic solutes. The utilization of online HDF (OL-HDF), where replacement fluid is pre-
pared by further purifying dialysate fluid instead of manufacturer-provided solutions has
made HDF more practical and more cost-effective. It is believed that high-volume OL-HDF
could potentially improve symptomatology, reduce morbidity, and may even improve survival
[8]. The number of worldwide patients receiving this modality has doubled between 2004 and
2010, and has reached 80,000 [9]. OL-HDF was officially approved for the treatment of ESRD
patients and for reimbursement by the Japanese health insurance system in 2012. Thereafter,
the number of OL-HDF patients in this country has been dramatically increasing [10].
Despite the data that suggests that OL-HDF can improve the patients symptoms, morbidity,
and survival in patients with ESRD, recent randomized clinical trials (RCTs) have failed to
demonstrate consistent results regarding improvement in QoL; hence, the magnitude of this
benefit, if present, remains uncertain [11–16]. To our knowledge, there has been only one evi-
dence synthesis that quantifies the QoL of patients on therapy with OL-HDF compared with
standard HD, nevertheless this study didn’t include any RCTs after 2007 [17]. Therefore, we
aimed to assess the body of evidence of the effectiveness of OL-HDF regarding the QoL in
patients with ESRD when compared to standard HD.
Methods
This study was conducted following guidance provided by the Cochrane Handbook for sys-
tematic reviews[18]; and it is reported in accordance to the recommendations set by the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) work group.
The protocol of this study has been deposited in protocols.io. and the identifier (DOI) of this
study has been assigned as dx.doi.org/10.17504/protocols.io.rhnd35e.
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Eligibility criteria
We included RCTs that compared OL-HDF against normal HD (high- or low-flux) in adult
patients with ESRD. We excluded RCTs that enrolled patients receiving off-line HDF or HF
and did not enroll any patients receiving OL-HDF. The outcome of interest was QoL of
patients with ESRD and we included any RCTs that contained QoL as one of their outcomes
regardless of its category as primary or secondary outcome. Any kind of scales assessing QoL
were included in this study. We included only RCTs in order to eliminate the disparity of the
difference in baseline characteristics of patients which might have affected their QoL.
Data sources and search strategy
A comprehensive literature search strategy with input from study investigators was designed
and carried out by an expert librarian in Mayo Clinic (Patricia J. Erwin) with experience in sys-
tematic reviews. The search strategy was performed using MEDLINE, EMBASE, The
Cochrane Database of Systematic Reviews, and The Cochrane Central Register of Controlled
Trials databases. The timeframe was from the databases inception to February 8, 2018 and no
language restriction was employed. The search strategy was highly sensitive and included key-
words and several combinations and variations of keywords like: Hemodiafiltration, ESRD,
clinical trial, and QoL. Additional references were sought from clinical experts (YU and KT).
The complete search strategy can be found on the supplementary material.
Study selection
The selection process consisted of a title and abstract screening phase and a full- text screening
phase (Fig 1). In both phases, each reference was screened by two reviewers in an indepen-
dently and in duplicate using standardized instructions; one of them was an expert in the con-
tent area (TS) and the other reviewer was a non-expert (FJBF). As part of calibration, eligibility
criteria were iterated for clarity and consistency. In the title and abstract screening level, both
reviewers must have agreed to exclude an article; conflicts were included. Following abstract
Fig 1. Process of study selection.
https://doi.org/10.1371/journal.pone.0205037.g001
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screening, eligibility of reports was assessed through full-text screening. Disagreements at the
full text screening phase were resolved by a consensus between both reviewers. When review-
ers couldn’t reach consensus, a third reviewer was consulted (YU or KT).
Data collection and management
The data from RCTs was extracted using a web-based standardized, and pilot tested data
extraction form. Data extraction was done in a duplicated and independent manner by two
reviewers (TS and FJBF). We abstracted data on inclusion criteria for each trial, patient demo-
graphics, baseline characteristics, sample size, intervention characteristics (parameters related
to OL-HDF and HD), follow-up time, scales assessing QoL, before and after scores of QoL,
loss to follow-up, and risk of bias indicators. The number of events in each trial was extracted,
when available, and attributed to the arm to which patients were randomized.
Risk of bias assessment
We used the Cochrane risk of bias assessment tool to assess the quality of the primary studies.
This tool takes into consideration six domains, (1) random sequence generation, (2) allocation
concealment, (3) blinding of participants, (4) incomplete outcome data, (5) selective outcome
reporting, and (6) other sources of bias. Two reviewers (TS and FJBF) independently assessed
each study´s quality by examining several domains: random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of outcome assessment, selec-
tive reporting, complete follow up, and other source of bias. Disagreements between the
reviewers were resolved by reaching a consensus. When reviewers couldn’t reach consensus, a
third reviewer was consulted (YU or RRG). The overall confidence or overall quality of evi-
dence for each outcome was appraised by discussion between the two extractors using the
Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
This approach takes into account the risk of bias of the individual studies, inconsistency in the
results, indirectness, imprecision and other considerations to provide a global assessment of
the confidence merited by the body of evidence [19].
Quality of life scales
The summary of QoL scales and assessment is shown in Table 1. Kantartzi et al. used Short
Form Health Survey with 36 questions (SF-36) questionnaire [International Quality of Life
Assessment Project (IQOLA) SF-36v1 Standard, Greece] to evaluate of QOL [15]. The SF-36
questionnaire is one of the most common methods of evaluating QOL worldwide [20,21]. The
8 domains of the SF-36 can be summarized in 2 scores: the physical component summary
score (PCS) and the mental component summary score (MCS); with higher scores indicating a
better health status [22]. Final scores have been normalized for the general population with a
mean value of 50 and an SD of 10. Mazairac et al., Morena et al. and Smith et al. used Kidney
Disease Quality of Life-Short Form (KDQOL-SF) to evaluate of QOL [11,12,14]. KDQOL
questionnaire consists of generic (SF-36) and kidney disease-specific (KDQOL) portions with
a range 0 to 100. Karkar et al. also used KDQOL-SF version 1.3, but they did no report PCS
and MCS [13]. Word et al. used Kidney Disease Questionnaire scored on a seven-point scale,
in which 1 is the worst possible score and 7 is the best possible score [16]. Since there were dif-
ferences in the scales for social activity, fatigue, and emotion, we adjusted these differences by
calculating standardized mean difference (SMD). Meanwhile, the scales for PCS and MCS
were same in all studies and the mean difference was calculated for PCS and MCS. Schiffl et al.
reported only one parameter of QOL (physical symptom of Kidney Disease Questionnaire),
therefore we excluded this study by Schiffl et al. from meta-analysis.
Effect of online HDF on quality of life in patients with ESRD
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Since most of the studies that evaluated QOL (4/7) included SF-PCS and MCS, we selected
these scores for meta-analysis. The rest of scales used in the studies were dissimilar (Table 2).
Therefore, we selected “Social activity”, “Fatigue”, and “Emotion” as scales for meta-analysis
because they were included at least 3 RCTs. Only 3 of the 6 studies reported QOL score at base-
line. Mazairac et al. reported QOL scores at baseline and difference from baseline score, and
we estimated QOL scores at follow-up from them. Morena et al. presented only graphs of QOL
scores, but after contacting them, they provided us the exact values.
Summary measures and data synthesis
We estimated the mean differences (MD) and standardized mean differences (SDM) and their
95% confidence interval (CI) and pooled all the studies’ effect size using a random-effects
model as described by DerSimonian and Kacker [23]. We chose random-effects model as our
main method of analysis because of its conservative summary of estimates and incorporation
of between- and within-study variability. To assess heterogeneity of treatment effect among tri-
als, we used the I2 statistic; this represents the proportion of heterogeneity of treatment effect
across trials that are not attributable to chance or random error. Hence, a value of 50% reflects
significant heterogeneity that is due to real differences in study populations, protocols, inter-
ventions, or outcomes [24]. The p value threshold for statistical significance was set at .05 for
effect sizes. Analyses were conducted using features on RevMan version 5.3 (The Nordic
Cochrane Center, Copenhagen, Denmark).
When necessary, we estimated the SD of QoL score at follow-up under the assumption that
SD of QoL score at follow-up might be same than that at baseline. Differences in the range of
the scales were adjusted by calculating SDM.
Finally, we analyzed the inter-observer agreement in the full text screening phase by calcu-
lating Cohen’s kappa coefficient, which resulted in substantial agreement (κ = .737).
Results
Characteristics of included studies
A total of 292 studies were identified by our initial electronic search strategy. Of which, 7
RCTs enrolling a total of 1,334 patients met the inclusion criteria. Five studies were carried out
Table 1. QOL scales and assessment.
Article QOL scale SF-PCS, MCS Other scales
(range of score)
Measurement point Baseline Follow-up Δ
Kantartzi 2013 SF-36 � 8 dimensions
(0–100)
3,6,9,12 M �
Karkar 2015 KDOQOL-SF version1.3 16 components
(0–100)
2 years �
Mazairac 2013 KDOQOL-SF version1.3 � 12 domeins
(0–100)
Baseline, 1,2,3 years � Possible to calculate �
Morena 2017 KDOQOL-SF version1.3 � Burden of kidney disease Baseline, 6,12,18,24 M Only Graphs Only Graphs
Smith 2017 KDOQOL-SF version1.3 � Baseline, 4, 8 weeks � �
Ward 2000 Kidney disease questionnaire 5 symptoms
(1–7)
6,12 M �
Schiffl
2007
Kidney disease questionnaire Physical symptoms (1–7) 52 weeks �
Description of the QoL scales included in the selected randomized clinical trials and characteristics of the assessment in each study.
� = Included, Δ = final vs. baseline difference.
https://doi.org/10.1371/journal.pone.0205037.t001
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in Europe, one study in Saudi Arabia, and 1 study in multiple countries. 2 of them were multi-
center trials and the other 5 were single-center. The Convective Transport Study (CON-
TRAST) was a RCT conducted in 29 dialysis centers in Netherlands, Canada, and Norway to
clarify the effect of OL-HDF on all-cause mortality and cardiovascular events [25]. A sub-anal-
ysis of CONTRAST focusing on QoL was published by Mazairac et al. in 2013 [14]. 3 of the 7
RCTs had a cross-over design. OL-HDF with post dilution was performed in all the included
studies. Convection volume for OL-HDF was over 15 L/session in all the studies. The full-char-
acteristics of the included studies are summarized in Table 3. The primary outcome of the 3
RCTs was QOL, but other 4 RCTs had different primary outcomes. The result of risk of bias
assessment is presented in Fig 2. Blinding of participants and personnel was unable to perform
in all studies because of the nature of the intervention. Therefore, performance bias was con-
sidered high risk for all included studies. Some of the studies included a high rate of lost to fol-
low-up, representing high risk of attrition bias in some RCTs (rates of follow up: Kantartzi
et al., 8.3%; Karkar et al., 0%; Mazairac et al., 94.4%; Morena et al., 31.5%; Smith et al., 14%;
Ward et al., 13.3%) (S1 Appendix: Summary of findings and confidence in the body of evi-
dence). Our outcomes were QOL scores filled by patients and assessing of these results was
Table 2. Other scales of QOL except for PCS and MCS.
Article Kantartzi 2013 Karkar 2015 Mazairac 2013 Morena 2017 Smith 2017 Ward 2000 Schiffl 2007
Burden of kidney � �
Social activity Social function � Social interaction Relationship with others
Physical symptoms � �
Physical functioning �
Role limitations-physical �
Fatigue Energy/fatigue General fatigue �
Emotion Emotional well-being General mood Depression
Role limitations-emotional �
Frustration �
Effects of kidney disease on daily life �
Work status � �
Cognitive function �
Sleep �
Overall health General health �
Patient satisfaction �
Bodily pain � �
Sexual performance �
Appetite �
Taste �
Skin color �
Sport activity �
Sickness �
Cramps �
Itching �
Post-dialysis fatigue �
Joint pain and stiffness �
Body energy �
Dialysis compliance �
Description of other scales (excluding PCS and MCS) included in the selected randomized clinical trials.
� = Included
https://doi.org/10.1371/journal.pone.0205037.t002
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Table 3. Trial description and baseline characteristics.
Author Year Place Study design N
total
N
HDF
N
HD
Age
(mean ± SD)
years old
Outcome Follow-up
(years)
Pre or post
dilution
Convection
volume (L/
section)
Comparison
Kantartzi 2013 Greece Single center
cross-over RCT
24 8 8 62.0 ± 13.3 QOL †
Biochemical
parameters
1 Post-
dilution
15–20 Low-flux
HD
Karkar 2015 Saudi
Arebia
Single center
RCT
72 36 36 54 ± 12 QOL †
Biochemical
parameters
2 Post-
dilution
19.3 ± 2.1 � High-flux
HD
Mazairac 2013 Netherland
Canada
Norway
Multicenter
RCT
712 356 356 64.1 ± 14.0 QOL † 5 Post-
dilution
24 Low-flux
HD
Morena 2017 France Multicenter
RCT
381 190 191 76.1 ± 6.7 Intradialytic
events †
All-cause of
death
QOL
Biochemical
parameters
2 Post-
dilution
16.46 ± 2.99 � High-flux
HD
Smith 2017 U.K. Single center
Cross-over RCT
100 50 50 65 ± 14 Recovery time †
Hypotension †
QOL
Biochemical
parameters
8 weeks Post-
dilution
20.6 High-flux
HD
Ward 2000 Germany Single center
RCT
45 24 21 61 ± 3
(OL-HDF)
52 ± 3 (HD)
QOL
Biochemical
parameters †
1 Post-
dilution
21 ± 1 � High-flux
HD
Schiffl 2007 Germany Single center
Cross-over RCT
76 38 38 62 ± 10 QOL
Biochemical
parameters †
Nutritional
status
52 weeks Post-
dilution
4.5 L/hour High-flux
HD
Description of the selected randomized clinical trials and the age of the participants at baseline.
Mean ± SD
† Primary outcome.
https://doi.org/10.1371/journal.pone.0205037.t003
Fig 2. Risk of bias assessment.
https://doi.org/10.1371/journal.pone.0205037.g002
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objective and less biased. Hence, bias for outcome assessment was considered in low risk.
Most of the included articles reported all results in the questionnaire they used. Some articles
did not report about random sequence generation and allocation concealment; therefore, they
were considered to be unclear. Crossover study design might have been affected by the “carry-
over effect” in which the effect of one treatment arm was carried to the next one, therefore the
category of other bias was considered unclear for crossover design studies.
Effect on physical component score (PCS)
On the meta-analysis of 4 studies assessing the effect on PCS (1,209 patients), OL-HDF was
associated with lower score of PCS compared to HD, but this was not statistically significant:
MD -0.77 (95% CI -1.94 to 0.41, p = 0.20) (Fig 3-1). I2 = 0%, low heterogeneity.
We then conducted a sensitivity analysis regarding the study design. We excluded the stud-
ies that had a cross-over design (Kantartzi 2013 and Smith 2017). This showed that OL-HDF
was associated with a lower score of PCS than HD, but this was not statistically significant:
MD -1.05 (95% CI -2.67 to 0.57, p = 0.20) (Fig 3-2). I2 = 0%, low heterogeneity.
Effect on mental component score (MCS)
On the meta-analysis of 4 studies assessing the effect on MCS (1,209 patients), OL-HDF was
associated with a lower score in MCS than HD, but this was not statistically significant: MD
-1.25 (95% CI -3.10 to 0.59, p = 0.18) (Fig 4-1). I2 = 26%, moderate heterogeneity.
We then conducted a sensitivity analysis excluding the studies by Kantartzi 2013 and Smith
2017. This showed that OL-HDF was associated with a lower score of MCS than HD, but this
was not statistically significant: MD -1.79 (95% CI -4.40 to 0.83, p = 0.18) (Fig 4-2). I2 = 66%,
moderate heterogeneity.
Effect on social activity
3 studies (845 patients) were included for this meta-analysis; where higher scores indicate a
better health status. In this meta-analysis, OL-HDF was associated with a statistically
Fig 3. Fig 3–1 Meta-analysis of PCS, Fig 3–2 Sensitivity analysis of PCS.
https://doi.org/10.1371/journal.pone.0205037.g003
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significant increase in the score of social activity when compared to HD: SMD 1.95 (95% CI
0.05 to 3.86, p = 0.04) (Fig 5-1). I2 = 97%, high heterogeneity.
We then conducted a sensitivity analysis excluding the study by Kantartzi 2013. This
showed that OL-HDF was still associated with a statistically significant increase in the score of
social activity when compared to HD: SMD 2.59 (95% CI 0.09 to 5.08, p = 0.04) (Fig 5-2). I2 =
98%, high heterogeneity.
Effect on fatigue. Three studies (133 patients) were included for this meta-analysis.
Higher scores indicated a better health status in the studies by Kantartzi et al. and Ward et al.,
Fig 4. Fig 4–1. Meta-analysis of MCS, Fig 4–2. Sensitivity analysis of MCS.
https://doi.org/10.1371/journal.pone.0205037.g004
Fig 5. Fig 5–1. Meta-analysis of Social Activity, Fig 5–2. Sensitivity analysis of Social Activity.
https://doi.org/10.1371/journal.pone.0205037.g005
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but higher scores indicated a worse health status in the study by Karkar, therefore, we inverted
the score in the study by Karkar et al. Results showed that, OL-HDF was associated with a
non-significant decrease in the score of fatigue when compared to HD: SMD 1.72 (95% CI
-1.49 to 4.94, p = 0.29) (Fig 6-1). I2 = 98%, high heterogeneity.
We then conducted a sensitivity analysis excluding the study by Kantartzi 2013. This
showed that OL-HDF was associated with non-significant decrease in the score of fatigue
when compared to HD: SMD 2.64 (95% CI -2.57 to 7.85, p = 0.32) (Fig 6-2). I2 = 99%, high
heterogeneity.
Effect on emotion
Three studies (133 patients) were included for a meta-analysis with higher scores indicating a
better health status. This meta-analysis showed that OL-HDF was associated with a non-signif-
icant increase in the score of emotion when compared to HD: SMD 2.04 (95% CI -0.65 to 4.73,
p = 0.14) (Fig 7-1). I2 = 97%, high heterogeneity.
We then conducted a sensitivity analysis excluding the study by Kantartzi 2013. This
showed that OL-HDF was associated with non-significant increase in the score of fatigue
when compared to HD: SMD 2.99 (95% CI -0.98 to 6.95, p = 0.14) (Fig 7-2). I2 = 98%, high
heterogeneity.
GRADE approach to assess the quality of evidence
Quality of evidence was moderate for the efficacy in Physical Component Score (PCS) and
Mental Component Score (MCS) due to risk of bias and nonsignificant effects (S2 Appendix:
Loss to Follow Up). In these categories, imprecision (effects were similar among studies) and
indirectness (studies reported actual scale scores) was not an issue. Regarding the construct of
Social Activity, quality of evidence was assessed as low because of indirectness (studies
reported these results in different manners) and risk of bias Although results for this construct
were heterogeneous (I2 = 95%), there was no substantial variation in the effect estimates across
studies. Finally, for the constructs of Fatigue and Emotion, quality of evidence was assessed as
Fig 6. Fig 6–1. Meta-analysis of Fatigue, Fig 6–2. Sensitivity analysis of Fatigue.
https://doi.org/10.1371/journal.pone.0205037.g006
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very low because of indirectness (different ways of reporting these among studies), imprecision
(high heterogeneity and variation in effect estimates across studies), and risk of bias.
Discussion
Main findings
This study aimed to assess whether OL-HDF improves QoL of patients compared to HD. We
found a significant reduction in the PCS score when comparing OL-HDF versus HD. Never-
theless, this difference was only of 0.81 in the range of 0 to 100. This is a small difference that,
despite its statistical significance, we consider that it must not be taken as a real clinical benefit.
Regarding MCS, the reduction was also small, only 1.24 points in a range from 0 to 100. We
also suggest having some precaution when interpreting these results. Kantartzi et al. reported
that convective modalities improved PCS and MCS as well as bodily pain when compared to
HD. Ward et al. did not report PCS and MCS, but they reported that, using the Kidney Disease
Questionnaire, OL-HDF resulted in a significant improvement of physical symptoms when
compared to HD. Mazairac et al. and Morena et al. reported that OL-HDF was related to a
lower score in the PCS and MCS when compared to HD, though they were not significant.
Taking this, and our meta-analytic results into account, we consider that the actual body of evi-
dence fails to demonstrate a real improvement in PCS and MCS scores when comparing
OL-HDF versus regular HD.
Regarding the other scales of QoL (Social activity, Fatigue, Emotion), all of the standardized
mean differences between OL-HDF and HD were small except for those in the study by Karkar
et al [13]. The results of the study by Karkar et al. resulted in incremental benefit of 7.8 SMD,
5.3 SMD, and 5.0 SMD, in the scores of Social activity, Fatigue, and Emotion, respectively
when comparing OL-HDF with HD. This large difference in results between the study by Kar-
kar et al. and other studies might have been the reason for high heterogeneity in these scales of
QoL. This study, used post-dilution OL-HDF with an average substitution fluid of 19.3 ± 2.1
liter per section for a total follow-up time of 24 months. These parameters are similar with
those in the rest of the included studies in this analysis (Kantartzi et al. and Ward et al.)
Fig 7. Fig 7–1. Meta-analysis of Emotion, Fig 7–2. Sensitivity analysis of Emotion.
https://doi.org/10.1371/journal.pone.0205037.g007
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However, the positive results of Karkar et al. might have been influenced by younger age of
samples (mean age of patients: 54.0 vs 62.0 vs 61 years old) and a different geographic region
of the primary site (Saudi Arabia vs Europe). [15,16]. Another limitation when analyzing the
study by Karkar et al. was that we didn’t know if the baseline score for QoL was same for both
groups because they did not report the baseline score. Nevertheless, their results suggest that
there might be an improvement in QoL, especially for younger patients, when comparing
OL-HDF versus regular HD.
Implications for clinical practice and research
QoL of patients is an important clinical outcome as well as mortality, and it’s also a predictor
for morbidity and mortality [26]. Previous studies have suggested a possibility of improvement
in QoL of patients even in a short period by reporting that convective therapies can reduce the
incidence of intradialytic hypotension and that OL-HDF is associated with greater hemody-
namic stability[27]. Surprisingly, our results suggest that there isn’t a real benefit provided by
OL-HDF on QoL when compared with regular HD within a time frame of five years of follow-
up. Better removal of middle molecules, β2 microglobulin, and phosphorus could also improve
clinical symptoms of patients with ESRD such as itching. Comparison of HD and hemodiafil-
tration with respect to QoL has produced contradictory results so far. A relatively large obser-
vational study by Canaud et al. reported that there was no difference across the dialysis
modalities when analyzing QoL of patients with ESRD. Meanwhile, a cross-sectional study
using SF-36 by Knezwic et al. reported that QoL in patients on OL-HDF was significantly bet-
ter than that in patients on HD with respect to most scales of SF-36 [28]. Nevertheless, there is
a difference in the mean age of the patients included in these studies, 63.5 and 56 years old in
the study of Canaud et al. and Knezevic et al., respectively. Therefore, this imbalance in age
may have influenced the differences in their results. The influence of this confounding factor
(age) can be supported also by the results of the study of Karkar et al. Therefore, we should
reconsider the administration of OL-HDF as a dialytic modality for treatment in elderly
patients because an improvement in QoL might not be achieved in a short period. On the
other hand, OL-HDF might be an effective option for improving QoL in younger patients.
Future RCTs should be done in larger number of young patients to clarify the effectiveness of
OL-HDF on QoL of patients with ESRD.
OL-HDF is thought to be associated better removal of both small and middle sized mole-
cules including β2 microglobulin [25,29]. Therefore, this modality could lead to an improve-
ment in the long-term complications of dialysis such as secondary amyloidosis. Nevertheless,
prospective studies with longer follow up periods would be necessary to evaluate this possible
long-term effectiveness of OL-HDF on QoL. Convection volume can be another important
factor to determine the effectiveness of this modality over conventional HD. However, average
convection volume in all the included studies was more than 15 L/section. Consequently, we
couldn’t assess the effect of convection volume on QoL on this study.
Strengths and limitations
One strength of this study was that we included only RCTs. In addition, we focused on
OL-HDF and excluded other convective therapies (off-line HDF or HF) to reduce the variabil-
ity in the effectiveness across convective therapies. In addition, the treatment-parameters used
with OL-HDF were relatively similar in all included studies. For example, all studies used post-
dilution modality and all of them had an average convection volume greater than 15L. There
are also some limitations in this study. First, as a comparison of OL-HDF, some studies
included patients on low-flux HD and others included patients on high-flux HD. The
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characteristics of enrolled patients were also variable among each study. Morena et al. targeted
only elderly patients over 65, and such differences might have influenced the results of this
study. Also, regarding the assessment of QoL, the follow-up periods were various and ranged
from 8 weeks to 5 years. This difference in follow up time might have affected the results of
our meta-analysis as well. The evaluation of QoL was assessed by patients themselves; there-
fore, scores could be quite subjective. All studies were unblinded and QoL was evaluated
through questionnaires; therefore, the risk of bias was high. Some papers did not provide the
baseline data, therefore we estimated some missing scores by calculating them, which might
have introduced some measurement bias. In addition, 2 of the 6 RCTs were crossover design.
Since most of the studies included in this meta-analysis were conducted in Europe, we can’t
truly generalize these results to the other part of the world. Also, the number of included stud-
ies was small and this made it difficult to evaluate the risk of publication bias. At last, the num-
ber of studies included in this meta-analysis is limited, therefore accumulation of studies
would be necessary to make stronger conclusions.
Conclusion
The body of evidence shows that OL-HDF does not improve QoL of patients when compared
to HD within a 5-year follow-up period. OL-HDF, yet, may be an effective option to improve
QoL in non-elderly patients. More and better quality evidence, however, is needed to have a
greater confidence and certainty in the estimates.
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